{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:09:13Z","timestamp":1788851353238,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    This retrospective study compared the efficacy and toxicity of concurrent triweekly versus weekly cisplatin in patients with previously untreated, biopsy\u2010proven NPC who received definitive CRT followed by adjuvant chemotherapy. Patients with distant metastasis, Karnofsky Performance Status\u2009&lt;\u200980, induction chemotherapy, or no adjuvant therapy were excluded. Medical records of 205 patients treated between June 2000 and June 2023 were reviewed. Patients received triweekly cisplatin (100\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    every 3\u2009weeks [administered as 50\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    on days 1 and 2 every 21\u2009days]) or weekly cisplatin (40\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ), with radiotherapy to 70\u2009Gy\/35 fractions or 69.96\u2009Gy\/33 fractions. Treatment outcomes were analyzed using the Kaplan\u2013Meier method and Cox proportional hazards model, while toxicity profiles were compared using the chi\u2010square test. After a median follow\u2010up of 76\u2009months, the 10\u2010year overall survival rate was 76.5%. The cumulative cisplatin dose was higher in the triweekly group (263.9\u2009\u00b1\u200950.1 vs. 247.8\u2009\u00b1\u200935.4\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0107), while the weekly group included more patients older than 50\u2009years (63.2% vs. 46.6%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0338). No significant differences were observed between the triweekly and weekly groups in overall survival (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.9096) and progression\u2010free survival (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.9186). The weekly cisplatin group exhibited a higher incidence of Grade 1\u20132 hypomagnesemia (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0415). Other acute toxicities, including gastrointestinal, renal, hematologic, otologic, neurologic, and electrolyte toxicities, as well as 1\u2010year post\u2010treatment kidney injury, hearing impairment, tinnitus, and peripheral neuropathy, were comparable between groups. These findings demonstrate similar survival outcomes and toxicity profiles between concurrent triweekly and weekly cisplatin regimens in NPC treated with curative CRT followed by adjuvant chemotherapy.\n                  <\/jats:p>","DOI":"10.1002\/ijc.70723","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:41:38Z","timestamp":1788849698000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Toxicity of Triweekly Versus Weekly Cisplatin in Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2729-696X","authenticated-orcid":false,"given":"Hao\u2010Shen","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irini","family":"Yacoub","sequence":"additional","affiliation":[{"name":"New York Proton Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Wong","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara A.","family":"Dunn","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren Scott","family":"Michel","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Kriplani","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"McBride","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Riaz","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab Abou","family":"Yehia","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphna Y.","family":"Gelblum","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achraf","family":"Shamseddine","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward Christopher","family":"Dee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology University of Chicago  New Lenox Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Julie","family":"Kang","sequence":"additional","affiliation":[{"name":"Yale University  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Sherman","sequence":"additional","affiliation":[{"name":"New York Proton Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"3","key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijrobp.2019.06.2549","article-title":"The Association Between the Development of Radiation Therapy, Image Technology, and Chemotherapy, and the Survival of Patients With Nasopharyngeal Carcinoma: A Cohort Study From 1990 to 2012","volume":"105","author":"Sun X. S.","year":"2019","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"4","key":"e_1_2_13_3_1","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy Versus Radiotherapy in Patients With Advanced Nasopharyngeal Cancer: Phase III Randomized Intergroup Study 0099","volume":"16","author":"Al\u2010Sarraf M.","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"e_1_2_13_4_1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2003.06.158","article-title":"Phase III Study of Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Nasopharyngeal Carcinoma: Positive Effect on Overall and Progression\u2010Free Survival","volume":"21","author":"Lin J. C.","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"28","key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"6966","DOI":"10.1200\/JCO.2004.00.7542","article-title":"Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally\u2010Advanced Nasopharyngeal Carcinoma: NPC\u20109901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group","volume":"23","author":"Lee A. W.","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijrobp.2005.06.037","article-title":"Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta\u2010Analysis of Eight Randomized Trials and 1753 Patients","volume":"64","author":"Baujat B.","year":"2006","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"2","key":"e_1_2_13_7_1","first-page":"C191","article-title":"Meta\u2010Analysis of Concurrent Chemoradiotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma","volume":"11","author":"Wang Y.","year":"2015","journal-title":"Journal of Cancer Research and Therapeutics"},{"issue":"21","key":"e_1_2_13_8_1","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1002\/cncr.30850","article-title":"A Multicenter, Phase 3, Randomized Trial of Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy Versus Radiotherapy Alone in Patients With Regionally Advanced Nasopharyngeal Carcinoma: 10\u2010Year Outcomes for Efficacy and Toxicity","volume":"123","author":"Lee A. W. M.","year":"2017","journal-title":"Cancer"},{"issue":"27","key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.1200\/JCO.2005.16.790","article-title":"Randomized Trial of Radiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy in Patients With American Joint Committee on Cancer\/International Union Against Cancer Stage III and IV Nasopharyngeal Cancer of the Endemic Variety","volume":"23","author":"Wee J.","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"23","key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/jnci\/djr432","article-title":"Concurrent Chemoradiotherapy vs Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: Phase III Randomized Trial","volume":"103","author":"Chen Q. Y.","year":"2011","journal-title":"Journal of the National Cancer Institute"},{"issue":"7","key":"e_1_2_13_11_1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/jnci\/dji084","article-title":"Overall Survival After Concurrent Cisplatin\u2010Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma","volume":"97","author":"Chan A. T.","year":"2005","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"e_1_2_13_12_1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.radonc.2015.11.030","article-title":"Comparison of Weekly Versus Triweekly Cisplatin Delivered Concurrently With Radiation Therapy in Patients With Locally Advanced Nasopharyngeal Cancer: A Multicenter Randomized Phase II Trial (KCSG\u2010HN10\u201002)","volume":"118","author":"Lee J. Y.","year":"2016","journal-title":"Radiotherapy and Oncology"},{"issue":"15","key":"e_1_2_13_13_1","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1200\/JCO.2017.35.15_suppl.6006","article-title":"Concurrent Chemoradiotherapy With 3\u2010Weekly Versus Weekly Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3 Multicentre Randomised Controlled Trial (ChiCTR\u2010TRC\u201012001979)","volume":"35","author":"Liang H.","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"e_1_2_13_14_1","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-20-4532","article-title":"A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients With Locoregionally Advanced Nasopharyngeal Cancer","volume":"27","author":"Xia W. X.","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_13_15_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.999027","article-title":"Efficacy and Safety of Weekly Versus Triweekly Cisplatin Treatment Concomitant With Radiotherapy for Locally Advanced Nasopharyngeal Carcinoma: A Systematic Review and Pooled Analysis","volume":"13","author":"Tian X.","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"52","key":"e_1_2_13_16_1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031842","article-title":"Efficacy and Safety of Weekly Versus Triweekly Cisplatin Concurrent With Radiotherapy in Nasopharyngeal Carcinoma: A Meta\u2010Analysis","volume":"101","author":"Chen L.","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"e_1_2_13_17_1","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1200\/JCO.2017.74.9457","article-title":"Once\u2010a\u2010Week Versus Once\u2010Every\u20103\u2010Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial","volume":"36","author":"Noronha V.","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"e_1_2_13_18_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ijc.33518","article-title":"Any Day, Split Halfway: Flexibility in Scheduling High\u2010Dose Cisplatin\u2010A Large Retrospective Review From a High\u2010Volume Cancer Center","volume":"149","author":"Kang J. J.","year":"2021","journal-title":"International Journal of Cancer"},{"key":"e_1_2_13_19_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106939","article-title":"Advances in Understanding Cisplatin\u2010Induced Toxicity: Molecular Mechanisms and Protective Strategies","volume":"203","author":"Elmorsy E. A.","year":"2024","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"10246","key":"e_1_2_13_20_1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0140-6736(20)30540-7","article-title":"The Link Between Kidney Disease and Cancer: Complications and Treatment","volume":"396","author":"Malyszko J.","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"e_1_2_13_21_1","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<866::AID-IJC34>3.0.CO;2-9","article-title":"Platinum Organ Toxicity and Possible Prevention in Patients With Testicular Cancer","volume":"83","author":"Hartmann J. T.","year":"1999","journal-title":"International Journal of Cancer"},{"issue":"2","key":"e_1_2_13_22_1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/phar.2500","article-title":"Cisplatin\u2010Induced Nephrotoxicity in an Outpatient Setting","volume":"41","author":"Burns C. V.","year":"2021","journal-title":"Pharmacotherapy"},{"issue":"1","key":"e_1_2_13_23_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7150\/jca.21357","article-title":"A Comparison of Weekly Versus 3\u2010Weekly Cisplatin During Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma Using Intensity Modulated Radiation Therapy: A Matched Study","volume":"9","author":"Meng D. F.","year":"2018","journal-title":"Journal of Cancer"},{"issue":"17","key":"e_1_2_13_24_1","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.7150\/jca.31663","article-title":"Long\u2010Term Survival and Prognostic Factors in Locoregionally Advanced Nasopharyngeal Carcinoma Patients Treated With TPF Induction Chemotherapy Followed by Cisplatin\u2010Combined Concurrent Chemoradiotherapy","volume":"10","author":"Zhang Q.","year":"2019","journal-title":"Journal of Cancer"},{"issue":"1","key":"e_1_2_13_25_1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/s40001-023-01297-y","article-title":"Weekly Versus Triweekly Cisplatin Treatment in Patients With Locally Advanced Nasopharyngeal Cancer During Concurrent Chemoradiotherapy","volume":"28","author":"Li X.","year":"2023","journal-title":"European Journal of Medical Research"},{"issue":"5","key":"e_1_2_13_26_1","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ijrobp.2018.04.069","article-title":"Concurrent\u2010Adjuvant Chemoradiation Therapy for Stage III\u2010IVB Nasopharyngeal Carcinoma\u2010Exploration for Achieving Optimal 10\u2010Year Therapeutic Ratio","volume":"101","author":"Ng W. T.","year":"2018","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"5","key":"e_1_2_13_27_1","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ejca.2010.10.026","article-title":"Factors Contributing to the Efficacy of Concurrent\u2010Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: Combined Analyses of NPC\u20109901 and NPC\u20109902 Trials","volume":"47","author":"Lee A. W.","year":"2011","journal-title":"European Journal of Cancer"},{"issue":"11","key":"e_1_2_13_28_1","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1634\/theoncologist.2016-0105","article-title":"Prognostic Value of the Cumulative Cisplatin Dose During Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Secondary Analysis of a Prospective Phase III Clinical Trial","volume":"21","author":"Peng H.","year":"2016","journal-title":"Oncologist"},{"issue":"16","key":"e_1_2_13_29_1","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.18632\/aging.204246","article-title":"Induction Versus Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Retrospective Cohort Study","volume":"14","author":"Mu X.","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"e_1_2_13_30_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.778836","article-title":"Efficacy and Safety of Concurrent Chemoradiotherapy Combined With Induction Chemotherapy or Adjuvant Chemotherapy in Patients With Stage II\u2010IVA Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis and Meta\u2010Analysis","volume":"11","author":"Yang J.","year":"2021","journal-title":"Frontiers in Oncology"},{"key":"e_1_2_13_31_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.104686","article-title":"Induction Versus Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Score\u2010Matched Analysis","volume":"105","author":"Tang S. Q.","year":"2020","journal-title":"Oral Oncology"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70723","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.70723","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:41:43Z","timestamp":1788849703000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.70723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":30,"alternative-id":["10.1002\/ijc.70723"],"URL":"https:\/\/doi.org\/10.1002\/ijc.70723","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"2026-05-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ijc.70723"}}